AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Aspira Women's Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.22−0.01 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $9.91M
- P/E (TTM)
- –
- Dividend yield
- –
Aspira Women's Health Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $9.22M | $9.18M | $9.15M | $7.97M | $6.57M | $4.54M | $4.40M | $2.77M | $2.85M | 2686.9% | +0.4% |
| Service [Member] | – | – | – | – | – | $13.00K | $112.00K | $281.00K | $268.00K | – | – |
| Genetics [Member] | – | – | $1.00K | $214.00K | $244.00K | $108.00K | $22.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Aspira Women's Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.